Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

Author:

Lee Myungsun,Mok Jeongha,Kim Deog Kyeom,Shim Tae Sun,Koh Won-Jung,Jeon Doosoo,Lee Taehoon,Lee Seung Heon,Kim Ju Sang,Park Jae Seuk,Lee Ji Yeon,Kim Song Yee,Lee Jae Ho,Jo Kyung-Wook,Jhun Byung Woo,Kang Young Ae,Ahn Joong Hyun,Kim Chang-Ki,Shin Soyoun,Song Taeksun,Shin Sung Jae,Kim Young Ran,Ahn Heejung,Hahn Seokyung,Won Ho Jeong,Jang Ji Yeon,Cho Sang Nae,Yim Jae-Joon

Funder

Korea Centers for Disease Control & Prevention

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Reference37 articles.

1. World Health Organization. Global tuberculosis report 2014. 2014

2. World Health Organization. Global tuberculosis report 2017. 2017

3. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis in Korea 2016. Cheongju: Korea Centers for Disease Control and Prevention; 2016. p. 44.

4. Jeon D. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea. Tuberc Respir Dis. 2017;80(4):336–43. https://doi.org/10.4046/trd.2017.0049 Epub 2017 Sep 1.

5. World Health Organization. Treatment guidelines for drug-resistant tuberculosis. 2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3